Market Overview

Eli Lilly Announces Negative Results of Solanezumab Phase 3 Trial

Share:
Related LLY
Technical Alert: Eli Lilly Unchanged After Wild Ride Following Q2 Report
Earnings Scheduled For July 26, 2016
Leadership transition at Lilly, CEO Lechleiter to retire at year end (Seeking Alpha)

Eli Lilly and Company (NYSE: LLY) today announced that the primary endpoints, both cognitive and functional, were not met in either of the two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in patients with mild-to-moderate Alzheimer's disease. However, a pre-specified secondary analysis of pooled data across both trials showed statistically significant slowing of cognitive decline in the overall study population of patients with mild-to-moderate Alzheimer's disease. In addition, pre-specified secondary subgroup analyses of pooled data across both studies showed a statistically significant slowing of cognitive decline in patients with mild Alzheimer's disease, but not in patients with moderate Alzheimer's disease.

Posted-In: News FDA

 

Related Articles (LLY)

View Comments and Join the Discussion!